News | CT Angiography (CTA) | February 14, 2017

NICE Guidance Recommends HeartFlow FFRct Analysis for Patients With Stable Chest Pain

U.K. committee concludes technology is safe, highly accurate and cost-effective solution for non-invasive evaluation

HeartFlow FFRct Analysis, NICE guidance, U.K., United Kingdom, guidelines, stable chest pain

February 14, 2017 — The National Institute for Health and Care Excellence (NICE) in the United Kingdom recently issued guidance for use of the HeartFlow FFRct (fractional flow reserve computed tomography) Analysis to help determine the cause of stable chest pain in patients. Developed by HeartFlow Inc., the HeartFlow FFRct Analysis is the first non-invasive technology to provide insight into both the extent of coronary artery disease and the impact that disease has on blood flow to the heart, enabling clinicians to select an appropriate treatment.

NICE recommends the HeartFlow FFRct Analysis for patients with stable recent onset chest pain. Based on the evidence, it concluded the technology is safe, has a high level of diagnostic accuracy and may avoid the need for invasive coronary angiography. The committee further concluded that, when compared to all other tests, use of the HeartFlow FFRct Analysis could save the U.K. National Health Service approximately £214 per patient through avoiding unnecessary invasive tests and treatment.

The new guidance follows chest pain guidelines issued by NICE in November 2016, recommending non-invasive coronary CT angiography (cCTA) as the initial diagnostic test for patients with stable chest pain. NICE now recommends the HeartFlow FFRct Analysis as the most cost-effective option when additional information is needed by the clinician.

HeartFlow’s process starts with data from a standard, non-invasive cCTA. Leveraging deep learning, an advanced form of artificial intelligence, HeartFlow creates a personalized, 3-D model of each patient’s arteries. Powerful computer algorithms then solve millions of complex equations to simulate blood flow and assess the impact of blockages in the arteries. With this actionable information, physicians can determine the right course of action for each patient.

“The HeartFlow FFRct Analysis provides a definitive understanding of both the anatomical and functional findings, without any additional testing or risk for patients,” said Joseph Mills, M.D., Liverpool Heart and Chest Hospital. “Application of the Heartflow FFRct Analysis is likely to transform the quality of care we can provide for patients, ensuring the most accurate diagnosis and the best treatment plan, as well reducing the need for invasive coronary angiography – a procedure not without its risks.”

Read the article “Clinical Applications of FFR-CT.”

VIDEO: Early U.S. Experience With FFR-CT in Evaluating ED Chest Pain Presentation

Read the article “One-Year PLATFORM Trial Results Reinforce Benefits of FFR-CT.”

Related Content

Videos | CT Angiography (CTA) | July 19, 2018
Kavitha Chinnaiyan, M.D., FACC, FSCCT, associate professor, Oakland University, William Beaumont School of Medicine,
Videos | CT Angiography (CTA) | July 18, 2018
A discussion with Gianluca Pontone, M.D., Ph.D., FSCCT, director of cardiovascular MRI, Centro Cardiologico Manzino,
Videos | CT Angiography (CTA) | July 17, 2018
A discussion with Todd Villines, M.D., FACC, FAHA, FSCCT, cardiologist, Georgetown Medical Center, and president of t
HeartFlow Announces New Commercial Coverage With UnitedHealthcare
News | CT Angiography (CTA) | July 03, 2018
HeartFlow Inc. announced that UnitedHealthcare now covers the HeartFlow FFRct Analysis, extending access to their 45...
Post-Mortem CT Angiography Illuminates Causes of Death
News | CT Angiography (CTA) | June 25, 2018
Computed tomography (CT) angiography is a useful adjunct to autopsy that is likely to increase the quality of post-...
iSchemaView Receives FDA Clearance for Rapid CTA
Technology | CT Angiography (CTA) | May 01, 2018
Cerebrovascular imaging analysis company iSchemaView received final clearance from the U.S. Food and Drug...
The use of metal artifact reduction software on this CCTA (CTA) cardiac CT from an Canon, Toshiba, Aquilion Precision, allows clear visualization inside a coronary stent. The 0.25 mm high-resolution reconstruction also helps delineate the various components of plaque.

The use of metal artifact reduction software on this Aquilion Precision image allows clear visualization inside a coronary stent. The 0.25 mm high-resolution reconstruction also helps delineate the various components of plaque.

Feature | CT Angiography (CTA) | April 26, 2018 | Dave Fornell
There have been a few big, recent advancements in cardiac computed tomography angiography (CCTA) imaging technology.
Siemens Healthineers, Florida Hospital Collaborate to Improve Healthcare Outcomes
News | CT Angiography (CTA) | January 23, 2018
January 23, 2018 – Siemens Healthineers and Florida Hospital, part of Adventist Health System, have announced a multi
Videos | CT Angiography (CTA) | July 21, 2017
DAIC and ITN Editor Dave Fornell discusses some of the most innovative new computed tomography (CT) technology and tr
Videos | CT Angiography (CTA) | July 18, 2017
Matthew Budoff, M.D., FACC, professor of medicine, David Geffen School of Medicine at UCLA, endowed chair of preventi
Overlay Init